VectivBio Announces Third Quarter 2021 Business Update
10 nov. 2021 08h30 HE
|
VectivBio AG
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with...
VectivBio Announces Results of Extraordinary General Meeting
03 sept. 2021 07h15 HE
|
VectivBio AG
BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio to Acquire Comet Therapeutics and Host R&D Day
31 août 2021 07h00 HE
|
VectivBio AG
- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -- VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE...